20
Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Embed Size (px)

Citation preview

Page 1: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Euretina Meeting 2013 Hamburg

Miles StanfordMedical Eye Unit

St Thomas’ HospitalLondon

Serpiginous choroiditis

Page 2: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditis

• Rare

• Bilateral

• 40-60 years

• Mainly caucasian

• Slight preponderance for men

Page 3: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditis - pathology

• Little available

• Widespread atrophy of photoreceptors, RPE and choriocapillaris

• Lymphocytic infiltration of the choroid

• Secondary choroidal neovascularisation

Page 4: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditis – clinical features

• Unilateral decrease in central vision, metamorphopsia or scotoma

• Little anterior segment reaction• Lesions classically peripapillary and then

spread outwards• Disease progression is stepwise and

asymmetric• Eventually permanent scar and subretinal

fibrosis

Page 5: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis
Page 6: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis
Page 7: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous – progression over 6 months

Page 8: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditis – stepwise progression over 18 months

Page 9: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Fluorescein angiography showing early masking and late staining on the edge of a old

scar

Page 10: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous – FFA staining at the edge of an old scar. These changes may be more evident on ICG

Page 11: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditisdifferential diagnosis

• APMPPE• Myopia• Choroidal ischaemia• Sarcoidosis• Toxoplasma• Tuberculosis/syphilis• Metastases/lymphoma• Retinochoroidal dystrophies

Page 12: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Ampiginous choroiditis (mantoux 20mm, subsequently developed Eales’ disease)

Page 13: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous-like choroiditis and TB• Presumed uveitis due to TB: All patients with 1 year

follow up, exclusion of other infections, +ve Mantoux, no recurrence after full anti TB treatment

• 26/192 (15%) patients with presumed TB-related posterior uveitis had serpiginous like choroiditis (OR 26; 95% CI 7.4-91.4)

• Sensitivity 14%: specificity 98%: positive predictive value 56%

• Not a good sign for screening but makes diagnosis 90% certain if positive

Gupta A et al Am J Ophthalmol 2010 149:562

Page 14: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous-like choroiditis and TB

• 11/21 (52%) patients tested +ve with Quantiferon compared to 9% HC and 13% uveitis controls

• 3/11 improved with specific anti-TB treatment

• ?directly due to bacteria or allergic response

Mackensen F et al Am J Ophthalmol 2008 146;761

Page 15: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous-like choroiditis and TB

• Comparison of 5 patients with serpiginous like (SLC) and classical serpiginous (SC)

• Patients with SLC were: - most likely to have come from a country

where TB endemic - To have unilateral multifocal disease with

significant vitritis - to have a positive PPD - to respond to tuberculostatic therapy

Arch Ophthalmol 2010 128: 853

Page 16: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditisInvestigations

• FFA

• ICG

• OCT

• Electrodiagnostics

• Visual fields

• Mantoux/IFN gamma

Page 17: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditis - complications

• CNVM occurs in 15-35%

• Usually arises from the edge of a scar but may be peripapillary

• Serous retinal or RPE detachments

• Subretinal fibrosis

• Rarely, CMO or NVs

Page 18: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditisTreatment

• Goals of therapy are to control active lesions rapidly and to prevent further recurrences and progression

• Steroids – oral or pulsed

• Other immunosuppressives

• Infliximab

• Treatment for secondary neovascularisation

Page 19: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditis - prognosis

• Very few long term studies

• Chronic, progressive disease in a stepwise manner

• Active lesions usually resolve over 3-6 months but may take longer

• Extrafoveal lesions may not give rise to symptoms and so pass unrecognised

Page 20: Euretina Meeting 2013 Hamburg Miles Stanford Medical Eye Unit St Thomas’ Hospital London Serpiginous choroiditis

Serpiginous choroiditis - Conclusions

• Rare, progressive disease of the middle-aged

• Must exclude TB especially if patient from endemic area

• Treat with standard immunosuppressives to control active lesions and prevent progression

• Potential for secondary CNVM